期刊
VACCINES
卷 9, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9080883
关键词
SARS-CoV-2; mRNA1273 vaccine; antibody response; methotrexate; adalimumab
Patients with rheumatoid arthritis (RA) may have weakened immune responses to the mRNA-1273 SARS-CoV-2 vaccine when treated with low-dose combination therapy of methotrexate and adalimumab, especially in elderly patients.
Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据